Encouraged by the therapeutic potential of BMI1 inhibition, we assessed the effect of PTC-318, a new and previously unpublished small molecule inhibitor of BMI1, on human cancer cells and evaluated its underlying mechanisms of action. This evidence concerns the gene BMI1 and cancer.